These results support the FDA recommendation that patients who are known to carry an altered UGT1A1 haplotype should be followed closely in order to detect AEs early and avoid the development of severe forms of neutropenia, diarrhea, anemia, and major toxicities in general [27,30,31]. This evidence concerns the gene UGT1A1 and Decreased total neutrophil count.